Bayer HealthCare Pharmaceuticals Inc., of Berkeley, Calif., and Onyx Pharmaceuticals Inc., of South San Francisco, said the FDA approved Bayer's Stivarga (regorafenib) for metastatic gastrointestinal stromal tumor previously treated with imatinib mesylate and sunitinib malate

Jennerex Biotherapeutics Inc., of San Francisco, said data demonstrating the ability of its lead product candidate, Pexa-Vec (JX-594, pexastimogene devacirepvec) to induce functional anticancer immunity, both in patients with diverse solid tumor types and in animal models has been published in the May 15 issue of Science Translational Medicine

Portola Pharmaceuticals Inc., of South San Francisco, Calif., reported safety and efficacy data from a Phase II proof-of-concept study of PRT4445 of Eliquis (apixaban) in healthy volunteers

Medgenics Inc., of San Francisco, said there have not been any procedure- or drug-related serious adverse events in the first four patients treated in the Phase IIa trial in Israel of Epodure biopumps for anemia in those on dialysis with end-stage renal disease...Oxigene Inc., of South San Francisco, completed enrollment of 110 patients in a Phase II trial of the antiangiogenic therapeutic Zybrestat (fosbretabulin) plus bevacizumab (Avastin, Genentech Inc.) to treat advanced ovarian cancer

Nektar Therapeutics Inc., of San Francisco, said partner Bayer AG, of Leverkusen, Germany, initiated patient enrollment in a Phase III program to test adjunctive aerosolized BAY41-6551 vs

Cytokinetics Inc., of South San Francisco, initiated a Phase I trial of CK-2127107 in healthy male volunteers

In separate news, InSite said the Court of Appeals for the Federal Circuit affirmed by a split decision the ruling of the Patent and Trademark Office panel of judges, which found in favor of the company in its patent interference litigation with the University of California, San Francisco, and confirmed inventorship of InSite patents protecting AzaSite, AzaSite Xtra and AzaSite Plus

Presidio Pharmaceuticals Inc., of San Francisco, said it entered a nonexclusive collaboration with Boehringer Ingelheim GmbH, of Ingelheim, Germany, for a Phase IIa trial testing an interferon-free, all-oral, direct-acting antiviral combination treatment for patients with hepatitis C virus (HCV) infection

Inc., of Whitehouse Station, N.J., said researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of Tredaptive (extended-release niacin/laropiprant) during the late-breaking clinical trial session at the American College of Cardiology 62nd Annual Scientific Session in San Francisco...Findings were presented during the late-breaking clinical trial session

The findings were reported in a late-breaking session at the American College of Cardiology's 62nd Annual Scientific Session in San Francisco and published online in the Journal of the American College of Cardiology

Data will be presented this weekend at the American College of Cardiology meeting in San Francisco

Tobira Therapeutics Inc., of South San Francisco, reported results from a Phase IIb trial of cenicriviroc, a once-daily dual CCR5/CCR2 inhibitor, at the Conference on Retroviruses and Opportunistic Infections in Atlanta

KaloBios Pharmaceuticals Inc., of South San Francisco, said data from its Phase I/II study of KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) in persistent asthma demonstrated preliminary safety, tolerability and signs of activity and support continued development of Humaneered antibody KB003

Adynxx Inc., of San Francisco, said the first patient was dosed in a Phase II study of AYX1 , its lead candidate to prevent post-surgical pain...Genentech Inc., of South San Francisco, a member of the Roche Group, and Novartis AG, of Basel, Switzerland, said results from a Phase III trial, ASTERIA II, demonstrated that omalizumab met its primary endpoint in patients with moderate to severe chronic idiopathic urticaria, who remained symptomatic despite treatment with approved H1 antihistamine doses

Onyx Pharmaceuticals Inc., of South San Francisco, said Leukemia published results from the Phase II study known as PX-171-005, testing Kyprolis (carfilzomib) in patients with relapsed and refractory multiple myeloma and varying degrees of renal insufficiency

Jennerex Inc., of San Francisco, said research was published in Cancer Research, demonstrating the ability of its lead product candidate, Pexa-Vec (JX-594), to disrupt the blood supply to a tumor

Nektar Therapeutics Inc., of San Francisco, said it started a Phase II study of etirinotecan pegol in patients with metastatic and recurrent non-small-cell lung cancer...Portola Pharmaceuticals Inc., of South San Francisco, inked a clinical collaboration with Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, and Bayer AG, of Leverkusen, Germany, to evaluate the safety of PRT4445, an antidote for Factor Xa inhibitors, in healthy volunteers to have been administered

Data were presented at the ASCO Gastrointestinal Cancers Symposium in San Francisco...The safety findings from the pivotal Phase II trial of belinostat, a pan-histone deacetylase inhibitor, featured in an oral presentation at the T-Cell Lymphoma Forum in San Francisco

Data were presented at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium in San Francisco